FDA OPDP Issues Untitled Letter to Exeltis Thomas Sullivan Nov 7, 2023 0 On August 11, 2023, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an…
